首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到19条相似文献,搜索用时 109 毫秒
1.
Background  Early loading statin therapy before percutaneous coronary intervention (PCI) is associated with reduced mortality and periprocedural myocardial injury. The aim of this study was to study the effect of rosuvastatin loading therapy before PCI in female patients with non-ST-segment elevation acute coronary syndrome (NSTEACS).
Methods  Consecutive 117 female patients with NSTEACS were randomly assigned to either the group of rosuvastatin loading before PCI (20 mg 12 hours before angioplasty procedure, with a further 10 mg dose 2 hours before procedure, the loading dose group, n=59) or the no rosuvastatin treatment group before PCI (control group, n=58). Periprocedural myocardial injury, periprocedural changes of high sensitivity C-reactive protein (hs-CRP), interleukin (IL)-1, IL-6, and tumor necrosis factor (TNF)-a in serum and the incidence of major adverse cardiac events (MACE) 3 months and 6 months later were assessed.
Results  The incidence of periprocedural myocardial injury was higher in control group than loading dose group (CKMB: 10.17% vs. 25.86% , P=0.027; Troponin I: 11.86% vs. 29.31%, P=0.019). MACE occurred in 1.69% of patients in loading dose group and 12.07% of those in control group 3 months after procedure (P=0.026), 3.39% vs. 17.24% at 6 months (P=0.014). The levels of hs-CRP, IL-1, IL-6, and TNF-a in serum were not significantly different between the two groups before PCI, but after PCI they were significantly higher in control group.
Conclusions  High-dose rosuvastatin loading before PCI significantly reduced periprocedural myocardial injury and periprocedural inflammation cytokines release and improved 3-month and 6-month clinical outcomes in female patients with NSTEACS who underwent PCI.  相似文献   

2.
Background  Systemic non-steroidal anti-inflammatory drugs have been evaluated for their possible preemptive analgesic effects. The efficacy of flurbiprofen axetil for preemptive analgesia in patients undergoing radical resection of esophageal carcinoma via the left thoracic approach needs further investigation. The aim of this study was to research the preemptive analgesic effects of flurbiprofen axetil in thoracic surgery, and the influence of preoperative administration on postoperative respiratory function.
Methods  This randomized, double-blind, controlled trial enrolled 60 patients undergoing radical resection of esophageal carcinoma via the left thoracic approach. Anesthesia management was standardized. Each patient was randomly assigned to receive either 100 mg flurbiprofen axetil intravenously 15 minutes before incision (PA group) or intravenous normal saline as a control (C group). Postoperative analgesia was with sufentanil delivered by patient-controlled analgesia pump. Postoperative sufentanil consumption, visual analog scale pain scores, plasma levels of interleukin-8, and oxygenation index were measured.
Results  Compared with the preoperative baseline, postoperative patients in the PA group had no obvious increase in pain scores (P >0.05), but patients in the C group had significantly increased pain scores (P <0.05). Pain scores in the C group were significantly higher at 24 hours postoperatively than preoperatively. Intergroup comparisons showed lower visual analog scale scores at 2–24 hours postoperatively in the PA group than the C group (P <0.05). Sufentanil consumption and plasma interleukin-8 levels at 2 and 12 hours postoperatively were significantly lower in the PA group than the C group (P <0.05). The oxygenation index at 2 and 12 hours postoperatively was significantly higher in the PA group than the C group (P <0.05).
Conclusions  Intravenous flurbiprofen axetil appears to have a preemptive analgesic effect in patients undergoing radical resection of esophageal carcinoma via the left thoracic approach, and appears to contribute to recovery of respiratory function and to reduction of the postoperative inflammatory reaction.
  相似文献   

3.
《中华医学杂志(英文版)》2012,125(19):3368-3372
Background  Anisodamine is widely used in therapy for treating acute glomerulonephritis and diabetic nephropathy because it can improve renal microcirculation. We performed a study to evaluate the preventive effects of anisodamine against contrast-induced nephropathy (CIN) in type 2 diabetics with renal insufficiency undergoing coronary angiography or angioplasty.
Methods  A total of 260 patients with type 2 diabetes and an estimated glomerular filtration rate (eGFR) of  60 ml-1 ∙ min-1 ∙ 1.73 m-2 or less, who were undergoing coronary angiography or angioplasty, were randomly assigned to receive an infusion of either sodium chloride (control group, n=128) or anisodamine (treatment group, n=132). Patients in the treatment group received an infusion of anisodamine at a rate of 0.2 μg ∙ kg-1 ∙ min-1 from 12 hours before to 12 hours after coronary angiography or angioplasty, while patients in the control group received an infusion of sodium chloride with the same volume as the treatment group. All patients received intravenous sodium chloride hydration. CIN was defined as a 25% increase in serum creatinine from baseline or an absolute increase of >0.5 mg/dl within three days after contrast exposure. The primary end point was the incidence of CIN. The secondary end point was a 25% or greater reduction in eGFR.
Results  There were no significant differences between the two groups with regard to age, gender, risk factors, laboratory results, medications and interventions. The incidence of CIN was 9.8% (13/132) in the treatment group and 20.3% (26/128) in the control group (P <0.05). The secondary end point was 6.0% (8/132) in the treatment group and 16.4% (21/128) in the control group (P <0.05).
Conclusion  These results indicate the preventive effects of anisodamine against CIN in type 2 diabetics with renal insufficiency who are undergoing coronary angiography or angioplasty.
  相似文献   

4.
Background  Cardiac arrest is one of the most serious complications of acute myocardial infarction (AMI), especially in the out-of-hospital patients. There is no general consensus as to whether percutaneous coronary intervention (PCI) is effective in treating ST-segment elevation myocardial infarction (STEMI) patients complicated by out-of-hospital cardiac arrest (OHCA). In our study, we evaluated the efficacy of PCI in treating STEMI patients complicated by OHCA through observing their clinical conditions in hospital; including total mortality, adverse cardiac events, stroke, acute renal failure, and gastrointestinal bleeding events.
Methods  A total of 1827 STEMI patients were enrolled in this study, where 81 were STEMI with OHCA. Between the patients with and without OHCA, and the OHCA patients with and without PCI, we compared the clinical characteristics during hospitalization, including total mortality and incidences of adverse cardiac events, and stroke.
Results  Compared to the patients without OHCA, the OHCA patients had significantly lower systolic blood pressure (P <0.05) and a faster heart rate (P <0.05), and a higher percentage of Killip class IV or Glasgow coma scale (GCS) ≤7 on admission (P <0.001). And the in-hospital mortality was higher in the OHCA patients (55.6% vs. 2.4%, P <0.001). Comparing the OHCA patients without PCI to the patients with PCI, there was no obvious difference of heart rate, blood pressure or the percentage of Killip class IV and GCS ≤7 on admission, but the incidences of cardiogenic shock, stroke were significantly lower in the with-PCI group during hospitalization (P <0.001, P <0.05). And the in-hospital mortality of the OHCA patients receiving PCI was significantly lower (36.7% vs. 84.3%, P <0.001).
Conclusions  During hospitalization, the incidence of adverse events and mortality are higher in the STEMI with OHCA patients, comparing with the STEMI without OHCA. Emergency PCI reduces the incidence of adverse events and decreases mortality during hospitalization, which is effective for treating STEMI with OHCA patients.
  相似文献   

5.
Background  Polyunsaturated omega-3 fatty acids may beneficially influence healing processes and patient outcomes. The aim of this research was to study the clinical efficacy of fish oil enriched total parenteral nutrition in elderly patients after colorectal cancer surgery.
Methods  Fifty-seven elderly patients with colorectal cancer were enrolled in this prospective, randomized, double-blind, controlled clinical trial. All patients received isocaloric and isonitrogenous total parenteral nutrition by continuous infusion (20–24 hours per day) for seven days after surgery. The control group (n=28) received 1.2 g/kg soybean oil per day, whereas the treatment group (n=29) received 0.2 g/kg fish oil and 1.0 g/kg soybean oil per day. Blood samples were taken pre-operatively, and at days one and eight after the operation. The plasma levels of CD4, CD8, CD4/CD8, interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α) were measured. Clinical outcomes were then analysed.
Results  Patient characteristics were comparable between the two groups. At day eight post-surgery, IL-6, TNF-α and CD8 titres were lower in the treatment group when compared to the control group; these results reached statistical significance. In the treatment group, there were fewer infectious complications and incidences of systemic inflammatory response syndrome (SIRS), and shorter lengths of hospital stay were observed. The total cost of medical care was comparable for the two groups. No serious adverse events occurred in either group.
Conclusions  Fish oil 0.2 g/kg per day administrated to elderly patients after colorectal surgery was safe and may shorten the length of hospital stay and improve clinical outcomes.
  相似文献   

6.
Background  Baseline white blood cell (WBC) count was correlated with ischemic events occurrence in patients with ST-elevated myocardial infarction (STEMI). However, circulating WBC count is altered after percutaneous coronary intervention (PCI). The aim of this study was to assess the relationship between postprocedural WBC count and clinical outcomes in STEMI patients who underwent PCI.
Methods  A total of 242 consecutive acute STEMI patients who underwent successful primary PCI were enrolled and followed up for two years. WBC counts were measured within 12 hours after PCI. ST-segment resolution (ST-R) and myocardial blush grades (MBG) were evaluated immediately after PCI. Left ventricular ejection fraction (LVEF) was obtained at baseline and 1218 months after PCI.
Results  Postprocedural WBC count was an independent inverse predictor of ST-R (OR 0.80, P <0.0001) and MBG 3 (OR 0.82, P <0.0001). It was negatively correlated with LVEF (baseline r=–0.22, P=0.001; 12–18 months r=–0.29, P <0.0001). The best cutoff value of WBC for predicting death was determined to be 13.0×109/L. The patients with a postprocedural WBC count above 13.0×109/L showed a significantly lower cumulative survival rate (30 days, 82.4% vs. 99.0%, P <0.0001 and 2 years 75.0% vs. 96.4%, P <0.0001). Multivariate Cox regression analysis showed that a postprocedural WBC count was a strong independent predictor of 30-day mortality (HR 8.48, P=0.019) and 2-year mortality (HR 4.93, P=0.009).
Conclusions  Increased postprocedural WBC count is correlated with myocardial malperfusion and left ventricular dysfunction, and is an independent predictor of poor clinical outcomes in STEMI patients who underwent PCI.
  相似文献   

7.
Background  Carotid stenosis is one of the common reasons for patients with ischemic stroke, and the two invasive options carotid endarterectomy (CEA) and carotid artery stenting (CAS) are the most popular treatments. But the relative efficacy and safety of the methods are not clear.
Methods  About 521 articles related to CAS and CEA for carotid stenosis published in 1995–2011 were retrieved from MEDLINE, Cochrane Library (CL), and China National Knowledge Infrastructure (CNKI) China Journal Full-Test database. Of them, eight articles were chosen. Meta-analysis was used to assess the relative risks.
Results  The eight studies included 3873 patients with symptomatic carotid artery stenosis, including 1941 cases in the carotid stent angioplasty group, and 1932 cases in the carotid endarterectomy group. Fixed effect model analysis showed that within 30 days of incidence of all types of strokes, surgery was significantly highly preferred in CAS patients (CAS group) than the CEA patients (CEA group), and the difference was statistically significant (relative ratio (RR)=1.80, 95% confidence interval (CI): 1.380–2.401, P <0.0001). But the incidence of death in the two groups is not showed and is not statistically significant after 30 days (RR=1.52, 95% CI: 0.82–2.82, P=0.18). The rate of cranial nerve injury in the CAS group is lower than the CEA group (RR=0.14, 95% CI: 0.05–0.43, P=0.0005). The incidence of CAS patients with myocardial infarction is lower than the CEA group after 30 days, but statistically meaningless (RR=0.22, 95% CI: 0.05–1.02, P=0.05). The stroke or death in CAS patients were higher than the CEA group after 1 year of treatment (RR=2.58, 95% CI: 1.03–6.48, P=0.04).
Conclusions  Compared to CAS, carotid endarterectomy is still the preferred treatment methodology of symptomatic carotid artery stenosis. Future meta-analyses should then be performed in long-term follow-up to support this treatment recommendation.
  相似文献   

8.
《中华医学杂志(英文版)》2012,125(21):3861-3867
Background  Left main coronary artery (LMCA) stenosis has been recognized as a risk factor for early death among patients undergoing coronary artery bypass grafting (CABG). This study aimed to assess if LMCA lesions pose an additional risk of early or mid-term mortality and/or a major adverse cardiac and cerebrovascular event (MACCE) after off-pump coronary artery bypass grafting (OPCABG), compared with non-left main coronary artery stenosis (non-mainstem disease).
Methods  From January 1, 2009 to December 31, 2010, 4869 patients had a primary isolated OPCABG procedure at Beijing Anzhen Hospital. According to the pathology of LMCA lesions, they were retrospectively classified as a non-mainstem disease group (n=3933) or a LMCA group (n=936). Propensity scores were used to match the two groups, patients from the non-mainstem disease group (n=831) were also randomly selected to match patients from the LMCA group (n=831). Freedom from MACCE in the two groups was calculated using the Kaplan-Meier method.
Results  The difference in the mortality and the rate of MACCE during the first 30 days between the non-mainstem disease group and the LMCA group did not reach statistical significance (P=0.429, P=0.127 respectively). With a mean follow-up of (12.8±7.5) months and a cumulative follow-up of 1769.6 patient-years, the difference in the freedom from MACCEs between the two groups, calculated through Kaplan-Meier method, did not reach statistical significance (P=0.831).
Conclusion  Analysis of a high volume of OPCABG procedures proved that LMCA lesions do not pose additional early and mid-term risk to OPCABG. Therefore, a LMCA lesion is as safe as non-mainstem disease lesion during the OPCABG procedure.
  相似文献   

9.
Background  The optimal revascularization strategy in patients with heart failure with preserved ejection fraction (HFPEF) remains unclear. The aim of the present study was to compare the effects of percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) in patients with HFPEF.
Methods  From July 2003 through September 2005, a total of 920 patients with coronary artery disease (CAD) and HFPEF (ejection fraction ≥50%) underwent PCI (n=350) or CABG (n=570). We compared the groups with respect to the primary outcome of mortality, and the secondary outcomes of main adverse cardiac and cerebral vascular events (MACCE), including death, myocardial infarction, stroke and repeat revascularization, at a median follow-up of 543 days.
Results  In-hospital mortality was significantly lower in the PCI group than in the CABG group (0.3% vs. 2.5%, adjusted P=0.016). During follow-up, there was no significant difference in the two groups with regard to mortality rates (2.3% vs. 3.5%, adjusted P=0.423). Patients receiving PCI had higher MACCE rates as compared with patients receiving CABG (13.4% vs. 4.0%, adjusted P <0.001), mainly due to higher rate of repeat revascularization (adjusted P <0.001). Independent predictors of mortality were age, New York Heart Association (NYHA) class and chronic total occlusion.
Conclusion  Among patients with CAD and HFPEF, PCI was shown to be as good as CABG with respect to the mortality rate, although there was a higher rate of repeat revascularization in patients undergoing PCI.
  相似文献   

10.
Background  Alpha 2A adrenergic receptor (AR) is a subtype of α2 AR belonging to G protein-coupled receptors, and exerts a variety of biological effects. Recent studies have demonstrated that the α2A AR activation was closely related with inflammatory reaction. The present study aimed to investigate the influence of α2A AR antagonist, yohimbine, on the severity of endotoxin-induced acute lung injury in rats.
Methods  A total of 72 male Sprague-Dawley rats were randomly divided into three groups: control group, lipopolysaccharide (LPS) group and LPS + yohimbine group. Rats were intratracheally administrated with normal saline or LPS (300 μg), and the rats in the LPS + yohimbine group were treated with additional yohimbine (2 mg/kg, i.p) soon after LPS administration. Six, 24 and 48 hours after treatment, arterial blood gas analysis was carried out, and optical microscopy was performed to evaluate pathological changes in the lung, and lung injury score was assessed. The count of white blood cells in bronchoalveolar lavage fluid (BALF) was determined. The levels of norepinephrine, tumor necrosis factor (TNF)-α, interleukin (IL)-1β and IL-6 in BALF were measured with enzyme-linked immunosorbent assay. Immunocytochemistry was performed for the detection of α2A AR on inflammatory cells in BALF.
Results  When compared with the control group, the oxygenation index in the LPS group was significantly decreased, and white blood cell count, the lung histopathological scores, levels of norepinephrine and IL-6 as well as α2A AR expression on inflammatory cells in the BALF were dramatically increased at different time points, and the concentrations of TNF-α and IL-1β were also increased except at 48 hours after LPS administration. The oxygenation index decreased while white blood cell count in BALF and the lung histopathological scores were obviously increased in the LPS + yohimbine group. The level of norepinephrine in BALF was increased at each time interval in the LPS + yohimbine group, and so did the levels of TNF-α, IL-1β and IL-6 at 6 and 48 hours after LPS administration respectively. When compared with the LPS group, the oxygenation index, white blood cell count, the lung histopathological scores and the level of IL-6 in the LPS + yohimbine group were significantly improved at each time interval, and the concentrations of TNF-α and IL-1β were also lower at 24 hours of LPS administration (all P <0.05). Correlation analysis indicated the level of norepinephrine was related to the levels of TNF-α, IL-1β and IL-6 in the BALF and the lung histopathological scores (r=0.703, r=0.595, r=0.487 and r=0.688, respectively, P <0.001) and the intensity scores of immunoreactivity to α2A AR on inflammatory cells were also associated with the levels of TNF-α, IL-1β and IL-6 as well as the lung histopathologial scores (r=0.803, r=0.978, r=0.716 and r=0.808, respectively, P <0.001).
Conclusions  Yohimbine can inhibit TNF-α, IL-1β and IL-6 overproduction and relieve the severity of pulmonary inflammation induced by endotoxin, which is maybe mediated by blockade of α2A AR on inflammatory cells.
  相似文献   

11.
目的:探讨急性心肌梗死患者接受急诊经皮冠状动脉介入治疗(PCI)后,新活素(冻干重组人脑利钠肽)对于对比剂肾病(CIN)的预防及肾功能的保护作用。方法:将88例急性心肌梗死接受急诊PCI治疗的患者随机分为试验组(45例)和对照组(43例),急诊PCI术后试验组即刻开始应用冻干重组人脑利钠肽0.007 5~0.015 μg/(kg·min),持续48~72 h,试验组及对照组术后均接受0.9%氯化钠生理盐水1 mL/(kg·min)持续水化治疗维持至术后12~24 h,分别于术前及术后48、72 h测定血清肌酐(SCr)、血清胱抑素C(Cys C)。结果:试验组PCI术后72 h较基线的SCr及估算的肾小球滤过率(eGFR)差值显著低于对照组(Scr升高值:5.33 vs.17.93, P=0.020;eGFR降低值:4.24 vs.12.18, P=0.008),同时试验组CIN发生率较对照组明显降低(P=0.042),Logistic回归分析显示应用冻干重组人脑利钠肽为CIN的保护因素(OR=0.04,95%CI:0.00~0.36)。结论:对于急性心肌梗死行急诊PCI治疗后应用冻干重组人脑利钠肽可保护肾功能,减少对比剂肾病发生率。  相似文献   

12.
目的探讨静脉应用重组人脑利钠肽(recombinant human brain natriuretic peptide,rhBNP)对急性前壁心肌梗死(acute anterior myocardial infarction, AAMI)合并糖尿病患者肾功能的影响。 方法连续入选行急诊经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)治疗的AAMI合并糖尿病患者53例。随机分为rhBNP组25例和硝酸甘油(nitroglycerine,NIT)组28例。2组在直接PCI治疗后分别给予rhBNP和硝酸甘油泵入72 h。比较2组用药前和用药后24 h、72 h、7 d血清肌酐(serum creatinine, SCr)、胱抑素C(cystatin C, CysC)和估测肾小球滤过率(estimated glomerular filtration rate,eGFR)。比较2组用药前和用药后24 h、7 d尿量、左心室射血分数(left ventricular ejection fraction,LVEF)、二尖瓣舒张早期血流峰值(E)与二尖瓣环舒张早期运动速度(e′)比值(E/e′)。随访观察30 d内主要不良心脏事件发生情况。 结果rhBNP组SCr、CysC水平呈先升高后降低趋势,eGFR呈先降低后升高趋势,用药后72 h时变化最明显,用药后7 d各项指标均恢复至接近基线水平。NIT组SCr、CysC、eGFR无明显改变。2组组间、时点间、组间·时点间交互作用差异有统计学意义(P<0.05)。用药后7 d ,2组24 h尿量均明显小于用药后24 h(P<0.05)。用药后7 d,rhBNP组LVEF水平高于用药后24 h,E/e′值低于用药后24 h,rhBNP组LVEF水平高于NIT组,E/e′值低于NIT组(P<0.05)。2组不良心脏事件发生率差异无统计学意义(P>0.05)。 结论静脉应用rhBNP对AAMI合并糖尿病患者心功能有一定程度改善作用,对肾功能可能存在一过性损伤,短期内可恢复,总体安全有效。  相似文献   

13.
目的探究急性冠状动脉综合征(acute coronary syndrome,ACS)患者经皮冠状动脉介入术(percutaneous coronary intervention,PCI)后外周血单个核细胞中微RNA-326(microRNA-326,miR-326)水平变化及意义。 方法前瞻性选取在首都医科大学附属北京潞河医院就诊的ACS患者205例作为研究对象。用密度梯度离心法获取外周血中单个核细胞;用实时荧光定量聚合酶链反应法检测单个核细胞中miR-326水平。用Cox回归分析和限制性立方样条分析miR-326与ACS患者预后的关系。 结果预后不良组和预后良好组miR-326水平随时间进展均呈升高趋势(P<0.05)。PCI后7 d miR-326诊断ACS患者预后的受试者工作特征曲线(receiver operating characteristic curve,ROC)下面积(area under the curve,AUC)高于PCI前miR-326和PCI后3 d miR-326诊断ACS患者预后的ROC AUC,差异均有统计学意义(P<0.05)。高miR-326组平均生存时间高于低miR-326组,差异有统计学意义(P<0.05)。Cox回归分析结果显示miR-362(HR=0.039,95%CI:0.016~0.098,P<0.05)是ACS患者预后的独立保护因素(P<0.05)。miR-362与ACS患者预后有关(P<0.05),且为非线性关系(P<0.05)。miR-326<0.24时,与miR-326=0.24比较,预后不良的风险升高;当miR-326>0.24时,与miR-326=0.24比较,预后不良的风险降低。 结论PCI后7 d miR-326与ACS患者预后有关。PCI后7 d miR-326水平低提示预后不良风险较高。  相似文献   

14.
 目的 探讨左卡尼汀对于预防急性冠脉综合征(acute coronary syndromes,ACS)患者冠状动脉造影(coronary artery angiography,CAG)和/或经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)术后发生对比剂肾病(contrast-induced nephropathy,CIN)的意义。方法 连续入选2016年1—12月复旦大学附属中山医院心内科诊断为ACS并接受CAG及PCI,并于围手术期接受左卡尼汀治疗的患者共416例,选取同期年龄、性别、基础肾功能匹配且未接受左卡尼汀治疗的ACS患者416例,探讨两组患者的CIN发生率。结果 左卡尼汀组CIN发生率(46/416,11.1%)与对照组(62/416,14.9%)差异无统计学意义。亚组分析中,肾功能正常患者的CIN发生率在左卡尼汀组(26/249例,10.4%)与对照组(28/252,11.1%)之间差异无统计学意义;肾功能轻中度异常(30 mL·min-1·1.73 m-2≤eGFR<90 mL·min-1·1.73 m-2)患者的CIN发生率在左卡尼汀组(20/167,13.2%)显著低于对照组(36/164,18.3%)(P=0.016)。整体研究人群中,低LVEF值、eGFR、HCT和对比剂用量是CIN的独立危险因素,肾功能轻中度异常人群中,低LVEF值、eGFR、HCT、HbA1C、对比剂用量和左卡尼汀使用情况是CIN的独立危险因素。结论 左卡尼汀未能显著降低肾功能正常的ACS患者的CIN发生率,但对于轻中度肾功能不全的ACS患者,在术前充分水化的基础上围手术期联合使用左卡尼汀可以显著降低CIN的发生率。  相似文献   

15.
目的了解冠心病患者择期冠状动脉介入治疗(percutaneous coronary intervention,PCI)术前服用大剂量阿托伐他汀对血清高敏C反应蛋白(high-sensitivity C-reactive protein,hs-CRP)及肾功能的影响。方法选择冠心病择期冠状动脉造影检查需要PCI治疗的患者173例,随机分为大剂量阿托伐他汀组(AS组,n=76)和常规治疗组(C组,n=97),治疗7天后行PCI术。术前和术后检测血清hs-CRP、血清肌酐(serum creatinine,SCr),计算肾小球滤过率(glo-merular filtration rate,GFR)。结果两组患者术前24h血hs-CRP水平,低于入院时(t=2.413和2.309,P〈0.05)和术后48h(t=2.087和2.368,P〈0.05);AS组PCI术前24h和术后48h血清hs-CRP均低于C组(t=2.007和2.275,P〈0.05)。两组PCI术后SCr较术前升高(t=2.464和2.392,P〈0.05),GFR较术前降低(t=2.496和2.573,P〈0.05);术后AS组SCr低于C组(t=2.337,P〈0.05),GFR高于C组(t=2.145,P〈0.05)。AS组对比剂肾病(contrast-induced nephropathy,CIN)发生率低于C组(6.58%vs16.49%,χ^2=3.93,P〈0.05)。结论冠心病择期PCI患者术前服用大剂量阿托伐他汀对CIN可能有良好的预防作用,机制可能与显著抑制炎症反应有关。  相似文献   

16.
目的:探讨急性心肌梗死病人经皮冠状动脉介入术(PCI)后发生对比剂肾病(CIN)的危险因素.方法:选取110例行急诊PCI治疗的急性心肌梗死病人,根据是否CIN分为CIN组和非CIN组,比较2组病人的一般资料、基础疾病、术前用药情况、对比剂使用情况等,分析CIN的危险因素.结果:2组病人的性别、年龄、体质量指数、血糖水平和血脂异常、高血压、既往心肌梗死、既往脑梗死例数差异均无统计学意义(P>0.05),而2组的肾功能不全、糖尿病、贫血例数和血清肌酐(SCr)、超敏C反应蛋白(hs-CRP)、血红蛋白水平及肾小球滤过率(eGFR)、左心室射血分数(LVEF)、肌酸激酶(CK)峰值、对比剂用量(CMV)差异均有统计学意义(P<0.05~P<0.01).其中,肾功能不全、SCr、eGFR、CMV、CMV/eGFR和LVEF、hs-CRP、对糖尿病、贫血均为CIN的独立影响因素(P<0.05~P<0.01).结论:除一般认为的肾功能不全、大剂量对比剂等危险因素外,糖尿病、高水平hs-CRP和CMV/eGFR等CIN危险因素也需引起足够重视.  相似文献   

17.
朱海 《中国医药导报》2014,(9):116-118,122
目的 探讨N-乙酰半胱氨酸在预防老年(年龄≥60岁)急性心肌梗死(AMI)患者急诊经皮冠状动脉内介入治疗术(PCI)后造影剂肾病(CIN)中的作用.方法 以2010年2月~2012年5月在北海市人民医院住院行急诊PCI的109例老年AMI患者为研究对象,随机分为水化+N-乙酰半胱氨酸治疗组(观察组,n=55)和水化+安慰剂治疗组(对照组,n=54).两组均同时予水化治疗,观察组在入院后即刻口服N-乙酰半胱氨酸泡腾片1200 mg,术后3d,口服N-乙酰半胱氨酸泡腾片1200 mg,2次/d;对照组则于相应的时间给予安慰剂治疗.术后24、48、72 h测定两组患者血清尿素氮(BUN)、血清肌酐(Scr)、肾小球滤过率(GFR)水平.结果 观察组出现CIN 5例;而对照组发生CIN 14例,两组CIN发生率差异有统计学意义(P<0.05);两组血管再通时间、支架数、造影剂用量比较[(6.25±l.82)min、(1.93±0.87)个、(158.7±36.2)mL比(6.78±l.63)min、(1.78±0.58)个、(150.9±33.2)mL],差异均无统计学意义(P>0.05);观察组术后72 h BUN、Scr[(8.23±2.37)mmol/L、(110.50±17.21)μmol/L]低于对照组[(9.47±3.90)mmol/L、(122.66±19.91) μmol/L],GFR高于对照组[(69.09±19.03)mL/min比(60.12±24.57)mL/min],差异有统计学意义(P<0.05).结论 N-乙酰半胱氨酸应用于老年急诊PCI患者可减少CIN的发生,有效保护患者肾功能,值得进一步研究.  相似文献   

18.
目的分析急性冠脉综合征(ACS)患者经皮冠状动脉介入治疗(PCI)后应用瑞舒伐他汀强化治疗的临床价值。方法选择2015年10月~2016年10月期间我院心血管内科和急诊ICU收治的72例ACS患者,并按随机数字法分为对照组和观察组。两组患者入院后均接受,术后并基于常规药物治疗;观察组在常规治疗的基础上增加瑞舒伐他汀的用药。详细记录测量的各数据,对比患者治疗前后的身体各项指标的变化情况,同时详细观察患者的预后情况。结果组内对比,患者的治疗1、3个月后的TG、TC、HDL-C及LDL-C各项血脂指标均优于治疗前;组间对比,观察组治疗后的TG、TC、HDL-C及LDL-C明显优于对照组治疗相同时间后的水平(P0.05)。组内对比,患者的治疗1、3个月后的IL-6、hs-CRP及TNF-α各项炎症因子均低于治疗前;组间对比,观察组的IL-6、hs-CRP及TNF-α各项炎症因子明显低于对照组治疗相同时间后的炎症因子含量(P0.05)。对比两组患者治疗后的预后情况,观察组的心血管事件发生4(11.11%)、再狭窄2(5.56%)明显低于对照组心血管事件发生9(25.00%)、再狭窄5(13.89%)(P0.05)。结论 ACS患者施PCI术后增加瑞舒伐他汀药物的强化治疗,可明显改善患者术后的血脂指标和炎症因子含量,并减少术后心血管事件发生及再狭窄的发生率,提高患者的临床效果,具有临床参考价值。  相似文献   

19.
目的:通过观察肾功能中度下降行经皮冠状动脉介入治疗(PCI)患者术前术后肾功能各项指标,评估前列地尔脂微球载体对肾脏的保护作用.方法:选择肾功能中度下降且行PCI治疗的患者40例,随机分为实验组及对照组.实验组术前12h静脉给予前列地尔脂微球载体20μg,术后改为10μg Qd应用3d.对照组术前12h~术后24h持续静脉给予生理盐水1ml/kg/h.检测入组前、术后24h、48h、72h的Scr、CysC、eGFR.记录不良事件.结果:实验组与对照组患者术后24h、48h、72h的Scr、eGFR、CysC水平无显著性差异(P>0.05).实验组未出现不良事件,对照组出现心功能恶化5例;2组均无对比剂肾病发生.结论:前列地尔脂微球载体对肾功能中度下降PCI患者具有肾脏保护作用,与水化疗效相同,但较少发生心功能恶化这一不良事件.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号